NovoCure Limited · NASDAQ:NVCR
NovoCure — Investor Presentation (September 2023)
37 slides from NovoCure's investor presentation, September 2023
Slide 1: Novocure September 2023
novecure’ yor M ~a ~ ‘ . SE ale Soh a Novocure September 2023 patientforward
Slide 2: Forward-looking statements
novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding a
Slide 3: Together with our patients, we strive to extend survival
together with our patients, 4 we Strive to extend survival in some of the most aggressive forms of cancer patientforward”
Slide 4: Tumor Treating Fields are electric fields that exert physical forces to kill cancer cells
novecure’ Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells GRAVITATIONAL FIELDS MAGNETIC FIELDS ELECTRIC FIELDS exert force on masses exert force on iron & exert force on charges & other magnets polarized molecules =) + @M@ + 4 Lt x x a Ll L K g ,
Slide 5: The cell membrane is a capacitor
novocure’ the cell membrane |s a capacitor TUNED ELECTRIC FIELDS DISRUPT PROTEINS DURING CELL DIVISION CAUSING CANCER CELL DEATH tumor cell healthy cell patientforwa rd” © 2023 Novocure GmbH 5
Slide 6: TTFields have multiple, distinct mechanisms of action
novecure’ TTFields have multiple, distinct mechanisms of action interference of disruption of 4 = . mitosis “ E mechanisms work together to selectively target and disrupt the progression of cancer cells, which can lead downregulation of . to their death > ar downstream L enhancement of cell movement
Slide 7: Optune is intended as a treatment for adult patients with GBM
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
Slide 8: Glioblastoma: malignant brain cancer
novecure’ glioblastoma: malignant brain cancer WHO grade 4 15,000 cases diagnosed in the U.S. each yeart 49.1% of primary malignant brain tumors? 14.6 to 16.7 months median overall survival® 65: median age of newly diagnosed GBM patient? Early detection is nearly 5-10% five-year survival rate imposs
Slide 9: Optune: proven to extend patient survival
novecure’ Optune: proven to extend patient survival EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM Overall survival (5-year survival analysis) a seen (ene | | #0 NEARLY HALF eo <0.001 ° of people using = 087 GNESI) _ O.SS10.550025) 43% Optune + TMZ 3 ord Optune (rans from diagnosis 24.5 19.8 =]
Slide 10: Optune: greater exposure increased survival
novecure’ Optune: greater exposure increased survival MEDIAN OVERALL SURVIVAL BY PERCENT OF TIME ON OPTUNE 25 months P-0.05 22 months P<0.05 Optune + TMZ 4 = TMZ al Bo montnsroes — OF PATIENTS RECEIVED A SURVIVAL M18 months 00s BENEFIT FROM OPTUNE BECAUSE | socom THEY USED IT >50% OF THE TIME 0 10 2
Slide 11: A comprehensive strategy for long-term growth
novecure’ a comprehensive strategy for long-term growth drive commercial advance deliver adoption clinical trials product innovation in approved to reach new patient to increase dose and indications populations duration of therapy Built upon a foundation of financial strength and a robust intellectu
Slide 12: Drive commercial adoption
novecure’ drive commercial adoption patientfo rward” © 2023Novocure GmbH 12
Slide 13: An established commercial business in GBM
an established commercial business in GBM 10 ACTIVE MARKETS SWEDEN FRANCE,,/ GERMANY. CANADA CHINA’ 5 @) @ M SWITZERLAND > AUSTRIA UNITED STATES Gia ren COVERED LIVES GLOBALLY 5,900+ S500M+ ACTIVE PATIENTS ON THERAPY ANNUAL NET REVENUES patientfo rward™ © 2023Novocure GmbH 13
Slide 14: Comprehensive approach to drive penetration in established markets
comprehensive approach to drive penetration in established markets patientforward” STRENGTHEN HCP RECOMMENDATION Educate HCPs on benefits of TTFields therapy INCREASE PATIENT DEMAND Arm patients to advocate for Optune® STREAMLINED ORGANIZATION Creation of U.S. CNS Cancers Franchise intended to renew
Slide 15: Advance clinical trials
novecure’ advance clinical trials patientfo rward” © 2023Novocure GmbH 15
Slide 16: Holistic strategy to expand TTFields clinical footprint
holistic strategy to expand TT Fields clinical footprint Investigate Expand labels use in new in approved indications L indications Explore additive effects with standards of care
Slide 17: Backbone therapy potential across a range of solid tumors
novecure’ backbone therapy potential with clinical versatility across a range of solid tumors and concurrent therapies IMMUNOTHERAPY Se atezolizumab pO ee = @ pembrolizumab Brain 7 a ~~ nivolumab Lung O.. 4 YY \ e CHEMOTHERAPY a. fp S y Tm — ™ LON Yaseen carboplatin ; _ } . : Pancreatic THIELDS |: P
Slide 18: Phase 3 LUNAR trial met primary overall survival endpoint
novecure’ phase 5 LUNAR trial met primary overall survival endpoint Overall survival (ITT population) Overall survival (ICl-treated patients) 10 1.0 09 09 Median OS (months) 13.2 99 Median OS (months) 18.5 10.8 08 Log-rank P-value 0.035, 08 Log-rank P-value 0.03 307 HR (95% Cl) 0.74 (0.56-0.98) 307
Slide 19: Planned commercial pathway to treat NSCLC patients
novecure’ planned commercial pathway to treat NSCLC patients 0 2023 5 2024 2025 L COMMERCIAL LAUNCH + Activate physici. d REGULATORY PATHWAY ee Een an patient education CLINICAL DATA v Initiate pre-PMA discussions programs y, ; with FDA * Treat on-protocol patients ABOUTISSS (eyllnts HESS Y Submit C
Slide 20: Enrollment complete and pivotal data anticipated in multiple phase 3 trials by year-end 2024
novecure’ enrollment complete and pivotal data anticipated in multiple phase & trials by year-end 2024 an) LUNAR METIS | PANOVA-3 Lung Cancer Brain Metastasis Pancreatic Cancer TRIAL COMPLETE MET PRIMARY ENDPOINT ENROLLMENT COMPLETE ENROLLMENT COMPLETE * Patients treated with TTFields + * Evaluating
Slide 21: Platform technology driving robust clinical pipeline
novecure’ platform technology driving robust clinical pipeline TRIAL TTFIELDS THERAPY + | PHASE 2 | PHASE 3 | APPROVED. EF-14 temozolomide newly diagnosed TRIDENT. temozolomide + radiation CNS glioblastoma temozolomide + program MaMNe see pembrolizumab paues recurrent glioblastoma EF-11 monotherapy
Slide 22: Deliver product innovation
novecure’ deliver product Innovation patientforward™ © 2023 Novocure GmbH 22
Slide 23: Product roadmap to prioritize dose and efficacy
product roadmap to prioritize dose and efficacy field generator arrays software applications next gen device new arrays MAXPOINT™ in development treating patients through planning software limited market release in development forward” © 2023 Novocure GmbH 23
Slide 24: Optimized dose delivered can lead to increased efficacy
novecure’ optimized dose delivered can lead to increased efficacy TUMOR TREATING FIELDS DOSE DELIVERED TIME ON xX FIELD INTENSITY xX CONDUCTIVITY om THERAPY TO TUMOR OF TISSUE —_ patientfo rward™ © 2023 Novocure GmbH 24 Ballo MT, et al. Correlation of Tumor Treating Fields Dosimetry to Survival Outc
Slide 25: New lighter, thinner arrays deliver greater intensity
novecure’ new lighter, thinner arrays deliver greater intensity an EXISTING ARRAYS NEW ARRAYS AP channel, 1,364 mAmps AP channel, 1,685 mAmps 0 V/cm LIMITED LAUCH OF NEW ARRAYS NOW IN AUSTRIA AND SWEDEN patientforward™ © 2023Novocure GmbH 25 ingthe as pa in Atray performance data obtained from pati
Slide 26: We strive to extend survival in some of the most aggressive forms of cancer
novocure’ _— SET we strive to extend survival < ee in some of the most aggressive forms of ca GLOBAL OFFICES TEAM MEMBERS innovation focus patientfo rward” da © 2023NovecureGmibli 26
Slide 27: Appendix
novocure’ appendix patientforward™
Slide 28: Therapy is frequency-tuned to target dividing cancer cells
novecure’ therapy is frequency-tuned to target dividing cancer cells | ——— TUMOR TREATING FIELDS 150 kHz 200 kHz Normal ntestine Intestin | | 50kHz 100 kHz 150 kHz 200 kHz 10 kHz 250 kHz Low Frequencies Intermediate High Frequencies DNA Damage cardiac defibrillator Frequencies radiofrequency ablatio
Slide 29: Ongoing trial designs
novecure’ ongoing trial designs - patientfo rward” © 2023Novocure GmbH 29
Slide 30: METIS phase 3 trial in brain metastases
novecure’ METIS phase 3 trial in brain metastases OPEN-LABEL, RANDOMIZED TRIAL DESIGN* screening and baseline evaluation MRI q2m until progression stereotactic 4 radiosurgery stereotactic . MRI q2m until radiosurgery progression METIS Brain Metastasis randomization 1:1 STUDY DESIGN 270 patients with
Slide 31: PANOVA-3 phase 3 trial in pancreatic cancer
novocure PANOVA-S phase 3 trial in pancreatic Ca OPEN-LABEL, RANDOMIZED TRIAL DESIGN! 6 sere : CT q8w until post-PD survival iv ; follow-up q4w ee iy : eraieltelaiing progression follow up visit pq baseline evaluation " 8 nab-paclitaxel + CT q8w until post-PD survival 8 gemcitabine progression follo
Slide 32: TRIDENT phase 3 trial in newly diagnosed GBM
novecure’ TRIDENT phase S trial in newly diagnosed GBM OPEN-LABEL, RANDOMIZED TRIAL DESIGN* TTFields + RT TTFields + + TMZ maintenance TMZ screening and baseline evaluation TTFields + maintenance TMZ RT + TMZ randomization 1:1 STUDY DESIGN + 950 patients with 24 month minimum follow-up Primary endpo
Slide 33: LUNAR-2 phase 3 trial in non-small cell lung cancer
novecure’ LUNAR-2 phase 3 trial in non-small cell lung cancer OPEN-LABEL RANDOMIZED TRIAL DESIGN lo’ TTFields + pembrolizumab + q3w until platinum-based chemotherapy screening and baseline evaluation pembrolizumab + platinum-based chemotherapy 9 6 a € ie} so) is © STUDY DESIGN LUNAR-2 + 734 patients
Slide 34: KEYNOTE B36 phase 2 trial in NSCLC
KEYNOTE B36 phase 2 trial in NSCLC OPEN-LABEL RANDOMIZED TRIAL DESIGN* 5 TTFields + mem follow-up q3w, ff survival = pembrolizumab CT qQw follow-up screening and baseline Sa evaluation Ex ae} é 7 : Ss pembrolizumab follow-up q3w, survival CT qQw follow-up STUDY DESIGN + 100 patients with 12-month mi
Slide 35: KEYNOTE D58 builds upon promising data from 2-THE-TOP phase 2 trial
novecure’ KEYNOTE D58 builds upon promising data from 2-1THE-TOP phase 2 trial ° N=26 patients Median PFS a N=26 patients Median OS 0 f r : 08 2-THE-TOP | 12.1 mos. = os 2-THE-TOP | 25.2 mos. < Gy Wh EF-14 matched-control | 7.9 mos. 2 °7 eal EF-14 matched-control | 15.9 mos. © 06 = 06 4 a \ (HR = 0.
Slide 36: Optune Lua and Optune indications for use and important safety information
novecure’ Optune Lua® and Optune® indications for use and important safety information INDICATIONS » Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of
Slide 37: Optune Lua and Optune indications for use and important safety information
novecure’ Optune Lua® and Optune® indications for use and important safety information WARNINGS AND PRECAUTIONS » Optune and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adverse event